C
Compo Biomedical Technology
Kangpu Bio-Pharma is a clinical stage company
About Compo Biomedical Technology
Kangpu Biopharmaceuticals is a pioneering company in the biopharmaceutical sector, focusing on the development of first-in-class and best-in-class drug candidates. Utilizing proprietary technology platforms such as NeoMIDES, SelPDEiS, and X SYNERGY, Kangpu aims to address significant unmet medical needs. The company operates in the global healthcare market, primarily targeting chronic and difficult-to-treat conditions like Crohn's disease. Kangpu serves a diverse range of clients, including healthcare providers, research institutions, and pharmaceutical companies. The business model is centered around research and development, with revenue generated through the commercialization of its patented drug candidates and strategic partnerships. Kangpu's commitment to innovation and collaboration is evident in its robust pipeline and global patent portfolio. The company is led by Dr. Cheng, who brings extensive experience in market access strategy and value proposition optimization for pharmaceuticals and medical devices. Kangpu's vision is to transform and improve lives globally through novel therapeutics based on innovative scientific solutions. The company values its dedicated and ambitious team, offering attractive salary and benefits packages, including equity incentives, to attract top talent worldwide.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2011
- Headquarters
- Huangpu, China
- Employees
- 12
- Open positions
- None listed
- Dealroom signal
- 38.6/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Aug 2023 | $14M | $172M | Realharmony Capital · Longpan Investment · NLVC · Yinxinggu Capital | ↗ |
| SERIES BOther financing | May 2021 | $34M | $138M | Ruihe Investment · Yijing Capital · Shining Capital · Zhongguancun Kaiyuan Capital | — |
Growth signals
Latest recorded traffic for Compo Biomedical Technology is 660 monthly website visits, down 52.9% over the last three months. Compo Biomedical Technology's team declined 14.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A14 investors entered at this stage
Shenzhen Guozhong Venture Capital Management
NLVC- FIFudan University Ningbo Research Institute
Lapam Capital- RIRuihe Investment
Yijing Capital- SCShining Capital
- ZCZhongguancun Kaiyuan Capital
ABC International Holdings- RCRealharmony Capital
- LILongpan Investment
- YCYinxinggu Capital
V-Capital- XCXiaochi Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Compo Biomedical Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Compo Biomedical Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.